Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.
WARNING LETTER
•Hubei Gedian Humanwell Pharmaceutical Co., Ltd.•November 7, 2025

Hubei Gedian Humanwell Pharmaceutical Co., Ltd. – FDA Warning Letter, Nov 7, 2025

Record Details

The FDA issued a warning letter to Hubei Gedian Humanwell Pharmaceutical Co., Ltd. following an inspection of its facility in Ezhou City, China, conducted from November 3 to 7, 2025. The inspection identified significant violations of Current Good Manufacturing Practice (CGMP) standards for active pharmaceutical ingredients (APIs), as defined under the Federal Food, Drug, and Cosmetic Act. The primary issues involved a failure to maintain manufacturing equipment properly. Specifically, investigators discovered scratches and stains on surfaces that come into contact with the product, suggesting that the equipment"s material is reacting with chemicals used in production. This poses a high risk of contaminating medicine with foreign particles. Additionally, the company’s Quality Unit failed to provide necessary oversight, neglecting to ensure that buildings were properly maintained and that equipment was suitable for its intended chemical processes. To address these deviations, the FDA requires the company to implement a comprehensive oversight plan for facility maintenance and conduct a retrospective quality review of all drug batches currently within their shelf life. The firm must also evaluate all manufacturing processes for material reactivity and provide a plan to empower its Quality Unit with better resources and authority. A formal response detailing these corrective steps is required within 15 working days. Failure to rectify these issues may lead to the FDA withholding drug approvals or refusing the entry of the company’s products into the United States.

Company
Hubei Gedian Humanwell Pharmaceutical Co., Ltd.
Inspection date
November 7, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · daf65d47-1cc8-411f-966d-f84379ef4087

Violation Codes5
FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)21 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Hubei Gedian Humanwell Pharmaceutical Co., Ltd.
  • 483 - 2025-11-07November 7, 2025
  • 483 - 2019-06-28June 28, 2019
  • 483 - 2016-05-13May 13, 2016
  • 483 - 2013-10-14October 14, 2013
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hubei Gedian Humanwell Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.